Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
NovaBay Pharmaceuticals (AMEX:NBY) reported its Q3 earnings results on Thursday, November 9, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
NovaBay Pharmaceuticals beat estimated earnings by 7.5%, reporting an EPS of $-0.37 versus an estimate of $-0.4.
Revenue was down $561 thousand from the same period last year.
Last quarter the company missed on EPS by $0.72 which was followed by a 7.14% drop in the share price the next day.
Here's a look at NovaBay Pharmaceuticals's past performance:
Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
---|---|---|---|---|
EPS Estimate | -0.55 | -0.91 | -0.17 | -1.05 |
EPS Actual | -1.27 | -0.85 | -1.47 | -3.50 |
Revenue Estimate | 3.67M | 3.20M | 5.10M | 3.75M |
Revenue Actual | 4.61M | 3.12M | 3.64M | 3.83M |
To track all earnings releases for NovaBay Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NBY